In recent years, immunotherapy has emerged as a promising therapeutic avenue for various cancers, with monoclonal antibodies targeting immune checkpoints, such as PD‐1 and CTLA‐4, demonstrating clinical efficacy across diverse tumor types. Here, PDCD1 is linked to neoplasm.